| NCT03380026 |
Mechlorethamine Induced Contact Dermatitis Avoidance Study |
https://ClinicalTrials.gov/show/NCT03380026 |
Recruiting |
Rochester Skin Lymphoma Medical Group, PLLC |
2019-12-13 |
| NCT03357224 |
PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT03357224 |
Recruiting |
European Organisation for Research and Treatment of Cancer - EORTC |
2021-09-30 |
| NCT03278782 |
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin |
https://ClinicalTrials.gov/show/NCT03278782 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-11-30 |
| NCT03063632 |
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma |
https://ClinicalTrials.gov/show/NCT03063632 |
Active, not recruiting |
National Cancer Institute (NCI) |
2021-05-01 |
| NCT03017820 |
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03017820 |
Recruiting |
Mayo Clinic |
2021-01-15 |
| NCT03011814 |
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03011814 |
Recruiting |
City of Hope Medical Center |
2023-03-08 |
| NCT02978625 |
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers |
https://ClinicalTrials.gov/show/NCT02978625 |
Recruiting |
National Cancer Institute (NCI) |
2021-06-01 |
| NCT02822586 |
TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome |
https://ClinicalTrials.gov/show/NCT02822586 |
Completed |
Virginia Commonwealth University |
2019-04-29 |
| NCT02652715 |
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02652715 |
Completed |
Mayo Clinic |
2018-12-21 |
| NCT03398161 |
Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT03398161 |
Recruiting |
M.D. Anderson Cancer Center |
2020-09-30 |
| NCT02542124 |
NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) |
https://ClinicalTrials.gov/show/NCT02542124 |
Active, not recruiting |
Neumedicines Inc. |
2019-02-28 |
| NCT02520791 |
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02520791 |
Recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT02448381 |
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) |
https://ClinicalTrials.gov/show/NCT02448381 |
Active, not recruiting |
Soligenix |
2019-12-31 |
| NCT02341209 |
Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02341209 |
Recruiting |
Rochester General Hospital |
2020-02-06 |
| NCT02243579 |
Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome |
https://ClinicalTrials.gov/show/NCT02243579 |
Completed |
National Cancer Institute (NCI) |
2018-01-04 |
| NCT02232516 |
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02232516 |
Recruiting |
Northwestern University |
2022-07-31 |
| NCT03385226 |
A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) |
https://ClinicalTrials.gov/show/NCT03385226 |
Recruiting |
University College, London |
2022-01-31 |
| NCT02168140 |
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02168140 |
Active, not recruiting |
Wake Forest University Health Sciences |
2019-04-18 |
| NCT01273766 |
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01273766 |
Completed |
Wake Forest University Health Sciences |
2012-03-31 |
| NCT02811783 |
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL |
https://ClinicalTrials.gov/show/NCT02811783 |
Recruiting |
Elorac, Inc. |
2022-06-30 |
| NCT01959477 |
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01959477 |
Completed |
Case Comprehensive Cancer Center |
2015-01-31 |
| NCT01839916 |
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01839916 |
Completed |
University of Chicago |
2018-08-31 |
| NCT01800838 |
Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01800838 |
Completed |
Case Comprehensive Cancer Center |
2014-09-30 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01748721 |
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT01748721 |
Completed |
Morphotek |
2015-05-31 |
| NCT01686594 |
PUVA Maintenance Therapy in Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT01686594 |
Completed |
Medical University of Graz |
2018-07-02 |
| NCT01678443 |
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01678443 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2011-04-11 |
| NCT01658319 |
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01658319 |
Completed |
Case Comprehensive Cancer Center |
2015-02-28 |
| NCT01590732 |
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01590732 |
Completed |
M.D. Anderson Cancer Center |
2018-05-02 |
| NCT01588015 |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01588015 |
Active, not recruiting |
City of Hope Medical Center |
2021-11-30 |
| NCT01578499 |
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) |
https://ClinicalTrials.gov/show/NCT01578499 |
Completed |
Takeda |
2016-05-31 |
| NCT01567709 |
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01567709 |
Completed |
National Cancer Institute (NCI) |
2018-03-29 |
| NCT01529827 |
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01529827 |
Completed |
Roswell Park Cancer Institute |
2015-05-28 |
| NCT01523223 |
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01523223 |
Completed |
Stanford University |
2016-09-30 |
| NCT01484015 |
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
https://ClinicalTrials.gov/show/NCT01484015 |
Completed |
Wake Forest University Health Sciences |
2012-06-30 |
| NCT01427881 |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01427881 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-06-30 |
| NCT01396070 |
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level |
https://ClinicalTrials.gov/show/NCT01396070 |
Completed |
Stanford University |
2015-04-30 |
| NCT01384513 |
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01384513 |
Recruiting |
Thomas Jefferson University |
2020-12-31 |
| NCT01352520 |
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) |
https://ClinicalTrials.gov/show/NCT01352520 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-01-31 |
| NCT01326702 |
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors |
https://ClinicalTrials.gov/show/NCT01326702 |
Completed |
National Cancer Institute (NCI) |
2015-04-30 |
| NCT04256018 |
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome |
https://ClinicalTrials.gov/show/NCT04256018 |
Recruiting |
Stanford University |
2022-02-28 |
| NCT04185220 |
Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome |
https://ClinicalTrials.gov/show/NCT04185220 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2023-03-01 |
| NCT04101331 |
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT04101331 |
Recruiting |
Affimed GmbH |
2022-04-30 |
| NCT03905135 |
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies |
https://ClinicalTrials.gov/show/NCT03905135 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2022-03-01 |
| NCT03902184 |
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03902184 |
Recruiting |
Innate Pharma |
2022-03-01 |
| NCT03837457 |
PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study |
https://ClinicalTrials.gov/show/NCT03837457 |
Enrolling by invitation |
miRagen Therapeutics, Inc. |
2021-12-31 |
| NCT03713320 |
SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT03713320 |
Active, not recruiting |
miRagen Therapeutics, Inc. |
2021-04-30 |
| NCT03695471 |
Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT03695471 |
Recruiting |
Mayo Clinic |
2022-10-11 |
| NCT03602157 |
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL |
https://ClinicalTrials.gov/show/NCT03602157 |
Recruiting |
UNC Lineberger Comprehensive Cancer Center |
2026-09-30 |
| NCT03598998 |
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT03598998 |
Recruiting |
City of Hope Medical Center |
2021-04-27 |
| NCT03587844 |
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients |
https://ClinicalTrials.gov/show/NCT03587844 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-07-31 |
| NCT03454945 |
Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT03454945 |
Recruiting |
Cairo University |
2019-04-01 |
| NCT01261247 |
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01261247 |
Active, not recruiting |
Mayo Clinic |
2016-05-09 |
| NCT01254578 |
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT01254578 |
Completed |
National Cancer Institute (NCI) |
2012-11-09 |
| NCT01233921 |
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT01233921 |
Completed |
Fred Hutchinson Cancer Research Center |
2012-07-31 |
| NCT01231919 |
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
https://ClinicalTrials.gov/show/NCT01231919 |
Completed |
National Cancer Institute (NCI) |
2013-04-30 |
| NCT01134341 |
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01134341 |
Completed |
Acrotech Biopharma LLC |
2015-08-31 |
| NCT01129193 |
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma |
https://ClinicalTrials.gov/show/NCT01129193 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-01-07 |
| NCT01129180 |
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01129180 |
Completed |
Ohio State University Comprehensive Cancer Center |
2012-05-31 |
| NCT01110135 |
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01110135 |
Completed |
University of Washington |
2013-11-30 |
| NCT01158274 |
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT01158274 |
Completed |
National Cancer Institute (NCI) |
2012-08-31 |
| NCT01075321 |
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01075321 |
Active, not recruiting |
Mayo Clinic |
2015-02-28 |
| NCT01073267 |
Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT01073267 |
Completed |
M.D. Anderson Cancer Center |
2014-12-31 |
| NCT01053494 |
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
https://ClinicalTrials.gov/show/NCT01053494 |
Completed |
Wake Forest University Health Sciences |
2012-02-29 |
| NCT00961220 |
O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00961220 |
Completed |
National Cancer Institute (NCI) |
2012-04-08 |
| NCT00918333 |
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00918333 |
Completed |
Mayo Clinic |
2015-12-01 |
| NCT00890747 |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
https://ClinicalTrials.gov/show/NCT00890747 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00856388 |
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders |
https://ClinicalTrials.gov/show/NCT00856388 |
Completed |
Roswell Park Cancer Institute |
2012-08-09 |
| NCT01258998 |
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma |
https://ClinicalTrials.gov/show/NCT01258998 |
Completed |
National Cancer Institute (NCI) |
2014-07-31 |
| NCT01805037 |
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
https://ClinicalTrials.gov/show/NCT01805037 |
Active, not recruiting |
Northwestern University |
2021-01-31 |
| NCT02953301 |
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) |
https://ClinicalTrials.gov/show/NCT02953301 |
Recruiting |
4SC AG |
2022-01-31 |
| NCT03281811 |
Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT03281811 |
Active, not recruiting |
Mayo Clinic |
2020-02-25 |
| NCT02580552 |
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL |
https://ClinicalTrials.gov/show/NCT02580552 |
Active, not recruiting |
miRagen Therapeutics, Inc. |
2020-12-31 |
| NCT01177371 |
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01177371 |
Completed |
Case Comprehensive Cancer Center |
2000-02-29 |
| NCT00769288 |
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00769288 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00611208 |
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT00611208 |
Completed |
Angimmune LLC |
2015-02-28 |
| NCT00608361 |
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00608361 |
Completed |
National Cancer Institute (NCI) |
2014-08-31 |
| NCT00601718 |
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00601718 |
Completed |
University of Washington |
2010-06-30 |
| NCT00535470 |
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT00535470 |
Completed |
Yaupon Therapeutics |
2011-03-31 |
| NCT00499811 |
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00499811 |
Completed |
National Cancer Institute (NCI) |
2011-08-31 |
| NCT00489203 |
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00489203 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00466921 |
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome |
https://ClinicalTrials.gov/show/NCT00466921 |
Active, not recruiting |
Northwestern University |
2020-02-29 |
| NCT00458731 |
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
https://ClinicalTrials.gov/show/NCT00458731 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT01093586 |
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01093586 |
Completed |
Case Comprehensive Cancer Center |
2015-12-31 |
| NCT00408681 |
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00408681 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00348985 |
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00348985 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00293345 |
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00293345 |
Completed |
National Cancer Institute (NCI) |
2012-10-31 |
| NCT00221039 |
Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A |
https://ClinicalTrials.gov/show/NCT00221039 |
Completed |
M.D. Anderson Cancer Center |
2011-04-05 |
| NCT00185965 |
CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas |
https://ClinicalTrials.gov/show/NCT00185965 |
Completed |
Stanford University |
2010-03-31 |
| NCT00178841 |
Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL |
https://ClinicalTrials.gov/show/NCT00178841 |
Completed |
Vanderbilt University |
2007-03-31 |
| NCT00168064 |
Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT00168064 |
Completed |
Yaupon Therapeutics |
2010-08-31 |
| NCT00118352 |
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00118352 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-07-31 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00103246 |
Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen’s Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT00103246 |
Completed |
Case Comprehensive Cancer Center |
2008-12-31 |
| NCT00098891 |
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00098891 |
Completed |
National Cancer Institute (NCI) |
2008-03-31 |
| NCT00091559 |
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) |
https://ClinicalTrials.gov/show/NCT00091559 |
Completed |
Merck Sharp & Dohme Corp. |
2005-11-23 |
| NCT00002479 |
Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome |
https://ClinicalTrials.gov/show/NCT00002479 |
Completed |
Northwestern University |
2002-08-31 |
| NCT00089271 |
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00089271 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00089011 |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00089011 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-03-31 |
| NCT00003196 |
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00003196 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-04-30 |
| NCT00006251 |
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
https://ClinicalTrials.gov/show/NCT00006251 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-09-30 |
| NCT00005080 |
506U78 in Treating Patients With Lymphoma |
https://ClinicalTrials.gov/show/NCT00005080 |
Completed |
National Cancer Institute (NCI) |
2006-01-31 |
| NCT00005799 |
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00005799 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-07-31 |
| NCT00078858 |
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00078858 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-01-31 |
| NCT00077155 |
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00077155 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00074087 |
Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT00074087 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2009-07-31 |
| NCT00072514 |
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00072514 |
Completed |
Fred Hutchinson Cancer Research Center |
2008-07-31 |
| NCT00003210 |
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00003210 |
Completed |
National Cancer Institute (NCI) |
2003-11-30 |
| NCT00066664 |
Serum Protein Patterns in Participants With Mycosis Fungoides/Cutaneous T-Cell Lymphoma, Psoriasis, or Normal Skin |
https://ClinicalTrials.gov/show/NCT00066664 |
Completed |
National Institutes of Health Clinical Center (CC) |
2007-12-31 |
| NCT00057967 |
Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome |
https://ClinicalTrials.gov/show/NCT00057967 |
Completed |
Northwestern University |
2007-06-26 |
| NCT00049504 |
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00049504 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-03-31 |
| NCT00047060 |
Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome |
https://ClinicalTrials.gov/show/NCT00047060 |
Completed |
National Institutes of Health Clinical Center (CC) |
2019-01-24 |
| NCT00040846 |
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00040846 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-12-31 |
| NCT00795769 |
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00795769 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-06-09 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00014235 |
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00014235 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-02-28 |
| NCT00004241 |
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma |
https://ClinicalTrials.gov/show/NCT00004241 |
Completed |
National Cancer Institute (NCI) |
2006-05-31 |
| NCT00003970 |
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00003970 |
Completed |
National Cancer Institute (NCI) |
2003-10-31 |
| NCT00002687 |
Interleukin-2 in Treating Patients With Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT00002687 |
Completed |
University of Washington |
2003-07-31 |
| NCT00051012 |
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT00051012 |
Completed |
Eisai Inc. |
2006-10-31 |
| NCT00050999 |
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients |
https://ClinicalTrials.gov/show/NCT00050999 |
Completed |
Eisai Inc. |
2006-09-30 |
| NCT00038376 |
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies |
https://ClinicalTrials.gov/show/NCT00038376 |
Completed |
M.D. Anderson Cancer Center |
2005-06-30 |